Chutes & Ladders — Califf appointed head of the FDA again after Woodcock’s long acting stint


Welcome to Chutes & Ladders this week, our roundup of hires, layoffs and retirements across the industry. Please send your store’s good or bad word to Kyle LaHucik, and we’ll feature it here at the end of each week.


Biden appoints Robert Califf as FDA chief after leading agency in Obama administration last year

US Food & Drug Administration
Robert califf, MD, has become President Joe Biden’s long-awaited candidate to lead the FDA.

The formal appointment came at the last minute, as Biden was required by law to appoint someone before November 15. The choice came 10 months after Biden’s inauguration and follows many months of calls from the industry to name someone, including a letter co-signed by Califf. himself. It was all the way back in April. Califf would take over from Janet Woodcock, MD, who served as Acting Commissioner for most of 2021. Fierce biotech


Biogen R&D chief Al Sandrock takes to exit ramp as company grapples with fallout from Aduhelm’s approval

Biogen
Al sandrock, MD, Ph.D., is at Biogen’s doorstep after a 23-year career in biopharma.

Sandrock is retiring from his senior R&D role as Biogen is reeling from the controversial development and approval of the Alzheimer’s disease drug Aduhelm as well as obstacles to commercialization since then. With more than two decades in biotechnology, Sandrock’s legacy is clouded by Aduhelm’s spotlight. It was not clear why the longtime leader is leaving as well as why he is leaving before a permanent successor is put in place. Fierce biotech


Pfizer CFO retires to become 3rd CEO of Big Pharma to announce exit plans this year

Pfizer
Frank D’Amelio is retiring from Pfizer as Chief Financial Officer and Executive Vice President of Global Sourcing and will remain as a consultant during the transition.

D’Amelio ends an almost 15-year stint at Big Pharma and has added nearly $ 150 billion in market capitalization growth to the company since taking on the role of CFO. Pfizer, President of Global Sourcing, Resumes Responsibility for Global Sourcing Mike McDermott. D’Amelio becomes the third senior Pfizer executive to announce retirement plans in recent months. leader in mergers and acquisitions Young Jean and director of development Rod MacKenzie, Ph.D., are also heading for the exit. Fierce pharma


> Provention Bio hired Jan Hillson, MD, as Senior Vice President of Clinical Development after holding the same role at Alpine Immune Sciences. Hillson is the third executive hired this month as the company awaits a Type A meeting with the FDA over its rejected Type 1 diabetes drug. Fierce biotech

> Another Vice President of Bluebird bio heads to AavantiBio as biotech is poached Jenny marlowe, Ph.D., as Scientific Director. Marlowe is the sixth executive hired this year at the one-year startup. Fierce biotech

> Managing Seagen for 15 years Nancy Merlan is now the CEO of the new biotechnology Reclusix Pharma. Fierce biotech

> Medtronic has named four new hires by early 2022. Bob hopkins as responsible for the overall strategy; Mei Jiang, as the new global leader in digital innovation; Harry “Jump” Kiil as chairman of the Cranial and Spinal Technologies unit; and Mira Sahney, chair of the pelvic health unit. Fierce MedTech

> IN8bio hired Gilead VP of Clinical Development Trishna goswami, MD, as Chief Medical Officer. Exit

> Teri loxam is the new COO and CFO of Kira Pharmaceuticals and replaces the interim CFO Matt Gorman. Loxam comes from SQZ Biotechnologies, where she was CFO. Exit

> Ram yeleswarapu joins Indegene as Senior Vice President after serving as President of CRO Navitas Life Sciences. Exit

> Innovative surgery named Memic Chad Zaring its sales manager, Duncan moffat its executive vice president of corporate operations and Stavit Cohen as vice president of R&D. Exit

> Catherine corzo is the new COO of cell coding company bit.bio after being a partner at Takeda Ventures and previously head of oncology cell therapy development at Big Pharma. Exit

> Memgen named Kevin coveney its CFO after having held the same position at Q-State Biosciences. Exit

> Immunitas Therapeutics selected as co-founder Amanda wagner as next CEO as current leader Jeffrey Goldberg retains an advisory role until the end of the year. Exit

> Robert shaw is the new CEO of Polypeptide Therapeutics Solutions after serving as Executive Director of the Standards Coordinating Body at Regenerative Medicine. Exit

> SpyBiotech named Simon jones its vice-president of finance and operations and occupies the position of interim finance director Vien Phan. Exit

> Pamela James, Ph.D., was promoted to Vice President of Products at Vector Laboratories. Exit

> The newly named insightful science and dotmatics combined Rebeca Sanchez Sarmiento as CFO after having held the same position at InvestCloud and ATTOM Data Solutions. Exit

> David Sherris, Ph.D., joins Penrose TherapeutTx as President and CEO after holding the same positions at GenAdam Therapeutics, Paloma Pharmaceuticals and VasculoMedics. Exit

> Cedilla Therapeutics appointed Joshua Murtie, Ph.D., as Vice President of Biology after having served as Senior Director at Servier Pharmaceuticals, and Chris Lindblom as Vice President of Finance after having held the same position at IFM Therapeutics. Exit

> Heidi hagen is the new CTO of Sonoma Biotherapeutics after serving as Interim CEO of Ziopharm Oncology and before co-founding software company Vineti. Exit

> Sylvaine case, Ph.D., is Lynx Biosciences’ first Commercial Director after serving as Vice President of Strategic Oncology Partnerships at Johnson & Johnson. Exit

> Puneet Arora, MD, is the new Medical Director of Lassen Therapeutics after serving as Clinical Manager of Inflammation and Immunology at Principia Biopharma of Sanofi. Exit

> Sanjay Aggarwal, is the new Chief Medical Officer of Apollo Therapeutics after having held the same position at Angiocrine Bioscience. Exit

> Blade Therapeutics appointed Bassem elmankabadi, MD, as Senior Vice President of Clinical Development after a position at FibroGen as Executive Medical Director overseeing the clinical development of the Fibrosis and Oncology programs. Exit


Comments are closed.